NR1I3 and metabolic dysfunction-associated steatotic liver disease: A PPARα-CAR inverse regulation has been implicated in inhibiting the β-oxidation of fatty acids, and CAR inverse agonists were proposed as potential drugs for non-alcoholic fatty liver disease (NAFLD) [16,17].